The Put That Pays Itself

How four executives make Stepstone the cleanest alt short.

STEP 0.00%↑ reports after the bell today. The number that matters isn’t on the press release — it’s the bill four men can hand the company in June, and who pays it.

❧ ❧ ❧

My readers know the private-credit games. Money raised against booked revenue instead of cash. PIK interest printed onto principal and then counted as income. A management fee charged on the gross carrying value, so the worse the loan gets the longer it sits on the books generating fees, and the wrapper — the rated CLO, the institutional syndicate — is engineered so the loss has somewhere to go, and that somewhere is retail. We have traced the vanishing footnote. We have read the scrubbed non-accruals. None of this is new. Most of it is poorly covered or filibustered, but the Mispriced Assets readership knows.

What is new is a company that has taken the same architecture and pointed it at a different problem: not how to hide a loss, but how to manufacture a gain, harvest a fee on it, and then hand the bill for the whole arrangement to its own public shareholders.

StepStone Group reports fiscal fourth-quarter and full-year results after the bell today. The sell side will talk about private wealth inflows, about SPRING’s return, about AUM crossing thresholds. They will treat the thing that actually matters — a soon to be $3 billion liability — as an accounting footnote. It is not a footnote. It is the equity story. Heroically, they are actually spinning it into a positive. “Accretive” they say.

If you have followed the sector, you already hold the comparables in your head, and StepStone is what you get when you fuse three of them into one animal.

It is Cliffwater’s model — write the enormous check to buy your way into the co-invest, pay up for access, and inherit the negative selection that rides along with being the marginal buyer who validates someone else’s mark; the deals you are allowed into are the deals someone else priced and passed on.

It is Brookfield’s opacity — hundreds of single-name SPVs and consolidated blockers where you cannot see what you own or what it is honestly worth.

And it is Hamilton Lane’s markups — paper appreciation booked as performance and skimmed as a fee. Any one of those is a reason to keep your hand on your wallet. StepStone is all three, stacked in one ticker.

And unlike the others, it comes with a catalyst — a date and a number — the massive dilution that starts sooner than people seem to understand.

This is a short report. I am positioned for this stock to fall, and below the line I lay out exactly why, in numbers you can check against tonight’s filing.

I. The bill comes due in June

In November 2022, StepStone struck an arrangement with the management team of its private-wealth business, SPW. The executives received a profits interest. Concurrently they signed an option agreement. Strip away the language and it says one thing: starting June 30, 2026, those executives — through an entity named CH Equity Partners — can put their interest back to StepStone and force the company to buy them out. StepStone can pay in cash, or it can elect to pay up to 75% in units that convert into Class A stock. The company itself, in its own risk factors, calls the price “substantial” and concedes it “may need to seek equity or debt financing” to fund it.

A year ago, in the filing for the year ended March 31, 2025, StepStone estimated the cash required to settle this liability at somewhere between $165.3 million and $661.1 million. That was the company’s own number. Then SPW did what it was built to do — it grew, it marked up, it crystallized fees — and the liability grew with it. By December 31, 2025, the liability-classified award on the balance sheet had ballooned to $2.166 billion, up from $663.9 million nine months earlier. Management has floated $3 billion as the eventual figure. The cash piece alone is now drifting toward $750 million against a “$661 million tops” estimate that is barely a year old.

The single fastest-growing, most-celebrated part of this company is the part public shareholders do not cleanly own — and the better it performs, the larger the check the public shareholders have to write to buy it. The purchase price is formulaic: SPW earnings, incentive components, a multiple that runs up to 20x. Bulls are capitalizing SPW’s growth into the stock at the same moment that growth is mechanically inflating the liability that will dilute them out of it. The flywheel and the noose are the same rope. The shareholders will be diluted ~30% for the business they think they already own.

II. Where the gains come from

So where does SPW’s growth — the growth that sets the put price — actually come from? Open SPRING.

The StepStone Private Venture and Growth Fund holds $3.34 billion in net assets. It carries those assets at a fair value of $3.22 billion against a cost of $2.41 billion — an $809 million, ~34% markup over what the fund paid. In the most recent six months, the fund booked $424 million of unrealized appreciation and $1.4 million of realized gain. Not a typo. For every dollar the fund actually realized, it marked up three hundred. The reported “performance” is almost entirely the adviser writing up its own positions — positions held through single-name SPVs, valued, per the fund’s own footnote, using marks that “have not been calculated, reviewed, verified or in any way approved by any general partner, manager or advisor” of the underlying companies.

And on those paper gains, the manager takes a cut: roughly $61 million of incentive fees booked in six months, against $1.4 million of realized profit. The fee is real and paid. The gain is a mark.

This is the machine. Buy a private position into an SPV, mark it up, book the markup as performance, charge an incentive fee on the markup, let the fee flow into SPW’s economics, let SPW’s economics inflate the buyout liability, and sell the whole experience to retail investors at the marked-up NAV, because retail is who you need — retail is the exit liquidity.

The institutions who price secondaries for a living are not paying these marks. StepStone moved away from institutional secondaries because they can’t rip off the people that know better.

III. The premium, and the analysts who defend it

A short thesis this clean usually shows up as a crowded short and a cratering multiple. Not here. Short interest sits around 7.5% — not crowded — and the stock trades at a premium. There is, as far as I can find, not one skeptical analyst covering it. The coverage is uniformly constructive, and it is constructive precisely because it has agreed to look at the wrong number.

The analysts wave away GAAP. GAAP net income is hundreds of millions negative every quarter, and the Street’s line is that this is “non-economic” — a non-cash remeasurement of the SPW award, noise, ignore it. That is exactly backwards. The GAAP charge is the economic cost. It is the accounting system telling you, quarter after quarter, what these executives are owed and what the rest of you will pay to satisfy it. Calling dilution “non-economic” does not make the shares you are about to be issued go away. It just means no one underwriting the stock has priced them.

IV. UBS math is not mathing

The bull rebuttal, the most coherent version of it, came from UBS about a month ago. Three claims: there is a lockup on the stock consideration, so dilution is deferred; the cash piece will be covered by debt; and the SPW executives are unlikely to exercise the put anyway. Take them in order, because none survives contact with the documents.

The lockup. The transfer restrictions are not a wall, they are a staircase: roughly 30% unrestricted immediately, then about 23.3% / 23.4% / 23.3% unlocking after years one, two, and three. That is not “dilution deferred.” That is a third of it live on day one and the rest on a clock. A lockup that releases is a timing argument dressed up as an economic one.

The debt. StepStone would need to raise on the order of $600–750 million in cash into a balance sheet that already pays out more than it earns in cash. Over the first nine months of FY26 the company generated $89.7 million of operating cash flow — and paid $94.4 million of dividends to public Class A shareholders, $125.4 million of distributions to legacy partners, employee owners, and other non-controlling-interest holders, and $12.6 million more under tax receivable agreements that route 85% of certain tax savings to the Class B/C/D partners and pre-IPO institutional investors. This is not just a dividend story. Cash is also leaving through the Up-C plumbing, and the public shareholder is one claimant among several who were written in ahead of him — all while the company carries existing debt and rising interest expense. And then there is the covenant nobody on the bull side seems to have opened: the company’s note agreement carries a 3.50x total net leverage covenant, and the definition of net debt only lets them net cash up to $100 million — not the full balance. You cannot park a billion dollars of cash on the balance sheet and net it away to stay onside. Layer a debt-funded buyout on top of that and you trip your own senior. The debt door the bulls are counting on is smaller than the thing they need to push through it. Michael Beatty’s debt financing idea is what I like to call a capital markets war crime.

They won’t exercise. Four men — Bob Long, Timothy Smith, Neil Menard, and Tom Sittema — hold the right to crystallize a multi-billion-dollar paper claim against a structure that is visibly destabilizing — negative GAAP equity on the horizon, a financing plan that doesn’t math, a stock priced for a story that the put itself contradicts. The assumption that they will politely sit on that option, year after year, rather than ring the register the first quarter they can, is not analysis. The cash portion of this windfall is many multiples of their combined career earnings.

V. The shape of it

Step back and the architecture resolves, the way it always does. The institutions wrote themselves 70% of SPW’s economics and a put with a 20x cap. The retail buyer funds the marks that set the price. The public shareholder absorbs the dilution that pays the bill. The analysts certify the number that hides it. And the people who built the structure get to choose the day it detonates.

The bear case does not require a collapse in private-wealth inflows. That would merely be accelerant. The problem is more elegant, and more annoying: the better SPW performs, the more expensive it becomes for StepStone’s public shareholders to buy the economics back. StepStone can keep raising money. SPW can keep growing. SPRING can keep marking up. The private-wealth machine can keep working exactly as advertised — and that is precisely the problem, because every dollar of success mechanically inflates the bill public shareholders have to fund.

Sometimes a footnote is a receipt. This time the receipt is two billion dollars and counting, it is on the balance sheet in plain sight.

After the bell, we find out how much bigger it got.

I don’t see much upside into the print. Every shareholder already knows these guys own some SpaceX, Anthropic, and Anduril. They’re marked up already and a small minority. I think this setup is as clean as it gets.

Nothing here is investment advice. I am short path through shares and puts and may exit my position at any time and without notice. Do your own work.